Scientific Resources
SARS-CoV-2 Antibody Semi-Quantitative Levels Is Important In The Management Of COVID-19 Vaccinations In Immunodeficiency Patients.
Abstract
To be presented by Joseph Chiao, MD at the 2023 American Academy of Allergy, Asthma, and Immunology Meeting in San Antonio, TX, 2/24/2023.
RATIONALE
The efficacy and durability of SARS-CoV-2 immunolog-
ical antibody response in Immunodeficiency Disorder (ID) patients (including Primary Immunodeficiency) can be utilized in their clinical
management to avoid COVID-19 infection. We correlated SARS-CoV-2
antibody semi-quantitative test results with ID patients’ COVID-19
vaccinations, their timing, IVIG infusions, and clinical outcomes.
METHODS
Retrospective EMR database review of ID patients from January 2021 to August 2022 tested by the semi-quantitative GenScript SARS-CoV-2 Neutralization Antibody Test. Statistical analysis of compiled data included the correlation between antibody titer test results,
vaccinations, IVIG therapy, and chart review for COVID-19-related health outcomes.
RESULTS
Antibody testing was performed four weeks after each ID patient was fully vaccinated (n599); 76% achieved positive antibody titers (low to high levels). Of the 23 initially negative antibody patients, 17 turned positive after 1 booster dose, 2 turned positive after the second
booster, and 2 needed the third booster; 2 patients failed to achieve even low titer levels (these 2 patients received Evusheld). Sustained high antibody levels typically persisted from 3 to 6 months. ID patients receiving IVIG tended to have longer sustained antibody titer levels in 2022 after vaccinations compared to 2021; we detected increasing SARS-CoV-2 antibody titers in IVIG products during 2022. No ID patients in this study were hospitalized or died due to COVID-19.
CONCLUSIONS
Our immunodeficiency disorder patients generally
produced a humoral immune response to the COVID-19 vaccine. However, the level of vaccination response and durability varies, therefore periodic monitoring of SARS-CoV-2 antibody semi-quantitative levels is important in the optimal management of ID patients.
